Literature DB >> 19834452

Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007.

.   

Abstract

Muscular dystrophies are a group of genetic diseases characterized by progressive skeletal muscle weakness and muscle cell death with replacement of muscle cells by fibrosis and fat. The most common muscular dystrophy in children is Duchenne muscular dystrophy (DMD), which predominantly affects males. Historically, DMD has resulted in loss of ambulation between ages 7 and 13 years and death in the teens or 20s. The average age at diagnosis is 5 years, despite earlier onset of symptoms. Becker muscular dystrophy is similar to DMD but has later onset and slower, more variable progression of symptoms. Birth prevalence of DMD has been estimated at 1 in 3,500 (2.9 per 10,000) male births and Becker muscular dystrophy at 1 in 18,518 (0.5 per 10,000) male births. To estimate the population-based prevalence of Duchenne/Becker muscular dystrophy (DBMD) and describe selected clinical outcomes, CDC and investigators from the Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet) analyzed data for males born during 1983-2002 that were reported to the MD STARnet from four participating states. This report summarizes those findings, which indicated overall state-specific prevalences on January 1, 2007, of 1.3-1.8 per 10,000 males aged 5--24 years. Among MD STARnet subjects, more than 90% of males with DBMD aged >or=15 years used wheelchairs. Nearly 60%percnt; of males with DBMD born during 1983-1987 had survived through 2007, emphasizing the need to develop and implement programs that address lifelong needs of males with DBMD.

Entities:  

Mesh:

Year:  2009        PMID: 19834452

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  54 in total

1.  Prednisolone treatment and restricted physical activity further compromise bone of mdx mice.

Authors:  S A Novotny; G L Warren; A S Lin; R E Guldberg; K A Baltgalvis; D A Lowe
Journal:  J Musculoskelet Neuronal Interact       Date:  2012-03       Impact factor: 2.041

2.  Fluoxetine prevents dystrophic changes in a zebrafish model of Duchenne muscular dystrophy.

Authors:  Trent A Waugh; Eric Horstick; Junguk Hur; Samuel W Jackson; Ann E Davidson; Xingli Li; James J Dowling
Journal:  Hum Mol Genet       Date:  2014-04-23       Impact factor: 6.150

3.  Use of state administrative data sources to study adolescents and young adults with rare conditions.

Authors:  J A Royer; J W Hardin; S McDermott; L Ouyang; J R Mann; O D Ozturk; J Bolen
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

4.  Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy.

Authors:  Elizabeth M McNally; Jonathan R Kaltman; D Woodrow Benson; Charles E Canter; Linda H Cripe; Dongsheng Duan; Jonathan D Finder; William J Groh; Eric P Hoffman; Daniel P Judge; Naomi Kertesz; Kathi Kinnett; Roxanne Kirsch; Joseph M Metzger; Gail D Pearson; Jill A Rafael-Fortney; Subha V Raman; Christopher F Spurney; Shari L Targum; Kathryn R Wagner; Larry W Markham
Journal:  Circulation       Date:  2015-05-05       Impact factor: 29.690

5.  Reproductive patterns among mothers of males diagnosed with Duchenne or Becker muscular dystrophy.

Authors:  Sarah K Nabukera; Paul A Romitti; Kristin M Caspers; Natalie Street; Christopher Cunniff; Katherine D Mathews; Deborah J Fox; Soman Puzhankara; Emma Ciafaloni; Katherine A James; Yin Su
Journal:  Am J Med Genet A       Date:  2012-12-13       Impact factor: 2.802

6.  Changes in muscle T2 and tissue damage after downhill running in mdx mice.

Authors:  Sunita Mathur; Ravneet S Vohra; Sean A Germain; Sean Forbes; Nathan D Bryant; Krista Vandenborne; Glenn A Walter
Journal:  Muscle Nerve       Date:  2011-04-12       Impact factor: 3.217

7.  Prevalence of Duchenne and Becker muscular dystrophies in the United States.

Authors:  Paul A Romitti; Yong Zhu; Soman Puzhankara; Katherine A James; Sarah K Nabukera; Gideon K D Zamba; Emma Ciafaloni; Christopher Cunniff; Charlotte M Druschel; Katherine D Mathews; Dennis J Matthews; F John Meaney; Jennifer G Andrews; Kristin M Caspers Conway; Deborah J Fox; Natalie Street; Melissa M Adams; Julie Bolen
Journal:  Pediatrics       Date:  2015-02-16       Impact factor: 7.124

Review 8.  Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data?

Authors:  Michele A Scully; Valerie A Cwik; Bruce C Marshall; Emma Ciafaloni; Jodi M Wolff; Thomas S Getchius; Robert C Griggs
Journal:  Neurology       Date:  2013-02-05       Impact factor: 9.910

9.  Muscular Dystrophy Surveillance, Tracking, and Research Network pilot: Population-based surveillance of major muscular dystrophies at four U.S. sites, 2007-2011.

Authors:  ThuyQuynh N Do; Natalie Street; Jennifer Donnelly; Melissa M Adams; Christopher Cunniff; Deborah J Fox; Richard O Weinert; Joyce Oleszek; Paul A Romitti; Christina P Westfield; Julie Bolen
Journal:  Birth Defects Res       Date:  2018-08-02       Impact factor: 2.344

10.  The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used.

Authors:  Craig M McDonald; Erik K Henricson; R Ted Abresch; Jay J Han; Diana M Escolar; Julaine M Florence; Tina Duong; Adrienne Arrieta; Paula R Clemens; Eric P Hoffman; Avital Cnaan
Journal:  Muscle Nerve       Date:  2013-05-16       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.